Share Price and Basic Stock Data
Last Updated: January 21, 2026, 6:31 pm
| PEG Ratio | 0.94 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Shreeoswal Seeds & Chemicals Ltd operates in the seeds, tissue culture, and biotechnology sector. The company reported total sales of ₹272 Cr for the fiscal year ending March 2023, a slight decline from ₹241 Cr in the previous year. However, the trailing twelve months (TTM) sales stood at ₹239 Cr, indicating a consistent performance despite fluctuations. Quarterly sales exhibited variability, with a peak of ₹86.62 Cr in December 2022 and a low of ₹26.27 Cr in March 2023. The revenue trajectory suggests a seasonal influence, commonly observed in the agricultural sector. The company aims to leverage its expertise in biotechnology to enhance product offerings and capture market share. The market capitalization currently stands at ₹125 Cr, reflecting a price-to-earnings ratio of 12.5, which is competitive compared to industry standards. This positioning may attract investors looking for growth in the agricultural biotechnology field, especially with increasing demand for innovative seed solutions in India.
Profitability and Efficiency Metrics
Shreeoswal reported an operating profit margin (OPM) of -8.87%, indicating challenges in maintaining profitability amidst rising expenses. The operating profit for the fiscal year 2025 was recorded at ₹10 Cr, a decrease from ₹12 Cr in 2023. The company’s net profit stood at ₹10 Cr, reflecting a net profit margin of 1.43%, which is below the typical sector range. The interest coverage ratio (ICR) of 2.31x demonstrates the company’s ability to meet interest obligations, albeit with limited headroom. Efficiency metrics reveal a cash conversion cycle (CCC) of 462 days, which is significantly elevated compared to the industry average, suggesting potential liquidity issues. The return on equity (ROE) was reported at 8.41%, while return on capital employed (ROCE) stood at 9.88%, both of which are relatively modest. These figures highlight the need for Shreeoswal to streamline operations and enhance cost management to improve profitability.
Balance Sheet Strength and Financial Ratios
Shreeoswal’s balance sheet reflects a mix of strengths and vulnerabilities. As of September 2025, total borrowings amounted to ₹47 Cr, against reserves of ₹30 Cr, indicating a reliance on debt financing. The company’s total liabilities were recorded at ₹123 Cr, with an equity capital of ₹18 Cr, leading to a debt-to-equity ratio of 0.95x, which is on the higher side compared to industry norms. The book value per share stood at ₹4.78, significantly lower than previous years, which may raise concerns among investors regarding asset management. Additionally, the current ratio of 1.56 suggests adequate liquidity to meet short-term obligations, but the quick ratio of 0.46 indicates potential challenges in covering immediate liabilities. The enterprise value (EV) of ₹148.16 Cr, relative to net operating revenue, reflects a cautious market sentiment towards the company’s growth potential. Overall, while the balance sheet shows some stability, the high debt levels necessitate careful monitoring.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Shreeoswal Seeds & Chemicals Ltd reveals a strong promoter holding of 66.63% as of September 2025, which reflects confidence from the company’s management. The public holding stands at 33.37%, with a substantial increase in the number of shareholders from 181 in September 2022 to 25,784 by September 2025, indicating growing investor interest. However, the absence of foreign institutional investment (FIIs) and limited domestic institutional investment (DIIs) may reflect caution among institutional investors regarding the company’s growth trajectory and profitability challenges. The steady promoter stake suggests a commitment to the company’s long-term strategy, while the increasing public shareholding may drive liquidity and market participation. This evolving shareholding landscape could influence future capital raising efforts and overall market perception of Shreeoswal.
Outlook, Risks, and Final Insight
Looking ahead, Shreeoswal Seeds & Chemicals Ltd faces both opportunities and challenges. The increasing demand for innovative seed solutions driven by climate change and sustainable agriculture practices presents growth potential. However, the company’s high cash conversion cycle and negative operating profit margin pose significant risks to its financial health. A focus on improving operational efficiency and cost management is critical for enhancing profitability. Additionally, the reliance on debt financing could strain future cash flows, particularly if sales do not rebound. Investors should remain vigilant regarding the company’s ability to navigate these challenges while capitalizing on market opportunities. Should Shreeoswal successfully enhance its operational efficiency and reduce debt levels, it could improve its financial standing and investor confidence, leading to a more favorable market outlook. Conversely, failure to address these issues may hinder growth and profitability, affecting long-term sustainability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 6.99 Cr. | 22.9 | 70.9/21.0 | 12.8 | 0.00 % | 11.8 % | 9.69 % | 10.0 | |
| Genesis IBRC India Ltd | 94.9 Cr. | 73.0 | 185/18.3 | 6.42 | 0.00 % | 51.6 % | 51.6 % | 10.0 | |
| Shreeoswal Seeds & Chemicals Ltd | 125 Cr. | 13.7 | 20.3/10.7 | 12.5 | 5.23 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 267 Cr. | 141 | 239/136 | 5.67 | 362 | 1.42 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 28.8 Cr. | 21.0 | 34.8/19.3 | 37.4 | 22.5 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 196.00 Cr | 54.32 | 18.52 | 81.79 | 0.28% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 32.69 | 86.62 | 26.27 | 83.32 | 65.55 | 76.74 | 43.42 | 76.95 | 67.69 | 75.42 | 25.85 | 97.95 | 39.44 |
| Expenses | 32.82 | 82.92 | 25.82 | 78.90 | 63.15 | 77.92 | 48.05 | 78.98 | 66.16 | 67.30 | 23.91 | 86.72 | 42.94 |
| Operating Profit | -0.13 | 3.70 | 0.45 | 4.42 | 2.40 | -1.18 | -4.63 | -2.03 | 1.53 | 8.12 | 1.94 | 11.23 | -3.50 |
| OPM % | -0.40% | 4.27% | 1.71% | 5.30% | 3.66% | -1.54% | -10.66% | -2.64% | 2.26% | 10.77% | 7.50% | 11.47% | -8.87% |
| Other Income | 0.02 | 0.02 | 0.07 | -0.00 | 0.01 | -0.00 | 0.09 | 0.01 | -0.00 | 0.05 | 0.24 | 0.07 | -0.00 |
| Interest | 0.84 | 1.51 | 0.53 | 1.49 | 1.38 | 1.54 | 1.57 | 1.45 | 0.95 | 0.75 | 1.12 | 1.05 | 0.94 |
| Depreciation | 0.10 | 0.11 | 0.12 | 0.12 | 0.14 | 0.17 | 0.08 | 0.13 | 0.13 | 0.12 | 0.12 | 0.15 | 0.19 |
| Profit before tax | -1.05 | 2.10 | -0.13 | 2.81 | 0.89 | -2.89 | -6.19 | -3.60 | 0.45 | 7.30 | 0.94 | 10.10 | -4.63 |
| Tax % | 23.81% | 20.95% | 76.92% | 28.11% | 28.09% | 14.88% | -43.30% | -24.44% | 31.11% | 26.44% | 40.43% | 27.92% | -30.67% |
| Net Profit | -1.30 | 1.66 | -0.23 | 2.03 | 0.64 | -3.32 | -3.51 | -2.72 | 0.32 | 5.37 | 0.55 | 7.28 | -3.20 |
| EPS in Rs | -0.14 | 0.18 | -0.03 | 0.22 | 0.07 | -0.36 | -0.38 | -0.30 | 0.03 | 0.59 | 0.06 | 0.80 | -0.35 |
Last Updated: January 10, 2026, 4:17 pm
Below is a detailed analysis of the quarterly data for Shreeoswal Seeds & Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 39.44 Cr.. The value appears to be declining and may need further review. It has decreased from 97.95 Cr. (Jun 2025) to 39.44 Cr., marking a decrease of 58.51 Cr..
- For Expenses, as of Sep 2025, the value is 42.94 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 86.72 Cr. (Jun 2025) to 42.94 Cr., marking a decrease of 43.78 Cr..
- For Operating Profit, as of Sep 2025, the value is -3.50 Cr.. The value appears to be declining and may need further review. It has decreased from 11.23 Cr. (Jun 2025) to -3.50 Cr., marking a decrease of 14.73 Cr..
- For OPM %, as of Sep 2025, the value is -8.87%. The value appears to be declining and may need further review. It has decreased from 11.47% (Jun 2025) to -8.87%, marking a decrease of 20.34%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.07 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 0.07 Cr..
- For Interest, as of Sep 2025, the value is 0.94 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.05 Cr. (Jun 2025) to 0.94 Cr., marking a decrease of 0.11 Cr..
- For Depreciation, as of Sep 2025, the value is 0.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.15 Cr. (Jun 2025) to 0.19 Cr., marking an increase of 0.04 Cr..
- For Profit before tax, as of Sep 2025, the value is -4.63 Cr.. The value appears to be declining and may need further review. It has decreased from 10.10 Cr. (Jun 2025) to -4.63 Cr., marking a decrease of 14.73 Cr..
- For Tax %, as of Sep 2025, the value is -30.67%. The value appears to be improving (decreasing) as expected. It has decreased from 27.92% (Jun 2025) to -30.67%, marking a decrease of 58.59%.
- For Net Profit, as of Sep 2025, the value is -3.20 Cr.. The value appears to be declining and may need further review. It has decreased from 7.28 Cr. (Jun 2025) to -3.20 Cr., marking a decrease of 10.48 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.35. The value appears to be declining and may need further review. It has decreased from 0.80 (Jun 2025) to -0.35, marking a decrease of 1.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:39 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 18 | 126 | 117 | 161 | 241 | 272 | 269 | 246 | 239 |
| Expenses | 16 | 120 | 110 | 154 | 230 | 260 | 268 | 236 | 221 |
| Operating Profit | 2 | 6 | 7 | 8 | 10 | 12 | 1 | 10 | 18 |
| OPM % | 10% | 5% | 6% | 5% | 4% | 4% | 0% | 4% | 7% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 2 | 2 | 2 | 3 | 4 | 6 | 4 | 4 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Profit before tax | 1 | 4 | 4 | 5 | 8 | 8 | -5 | 5 | 14 |
| Tax % | 20% | 26% | 28% | 28% | 28% | 28% | -23% | 31% | |
| Net Profit | 1 | 3 | 3 | 4 | 5 | 6 | -4 | 4 | 10 |
| EPS in Rs | 0.18 | 0.31 | 0.33 | 0.40 | 0.59 | 0.62 | -0.45 | 0.39 | 1.10 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 200.00% | 0.00% | 33.33% | 25.00% | 20.00% | -166.67% | 200.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.00% | 33.33% | -8.33% | -5.00% | -186.67% | 366.67% |
Shreeoswal Seeds & Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 1% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | -13% |
| TTM: | 252% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 0% |
| 1 Year: | -53% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 4% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 1:31 pm
Balance Sheet
Last Updated: December 10, 2025, 3:24 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 15 | 15 | 15 | 15 | 15 | 18 | 18 | 18 |
| Reserves | 1 | 11 | 14 | 18 | 23 | 29 | 22 | 25 | 30 |
| Borrowings | 25 | 24 | 30 | 43 | 42 | 41 | 64 | 42 | 47 |
| Other Liabilities | 15 | 11 | 7 | 16 | 40 | 43 | 20 | 19 | 28 |
| Total Liabilities | 52 | 61 | 66 | 93 | 120 | 128 | 124 | 105 | 123 |
| Fixed Assets | 2 | 2 | 4 | 4 | 4 | 4 | 7 | 6 | 8 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 50 | 59 | 63 | 89 | 115 | 122 | 115 | 96 | 114 |
| Total Assets | 52 | 61 | 66 | 93 | 120 | 128 | 124 | 105 | 123 |
Below is a detailed analysis of the balance sheet data for Shreeoswal Seeds & Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00 Cr..
- For Reserves, as of Sep 2025, the value is 30.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 30.00 Cr., marking an increase of 5.00 Cr..
- For Borrowings, as of Sep 2025, the value is 47.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 42.00 Cr. (Mar 2025) to 47.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 28.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Mar 2025) to 28.00 Cr., marking an increase of 9.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 123.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 105.00 Cr. (Mar 2025) to 123.00 Cr., marking an increase of 18.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 96.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 18.00 Cr..
- For Total Assets, as of Sep 2025, the value is 123.00 Cr.. The value appears strong and on an upward trend. It has increased from 105.00 Cr. (Mar 2025) to 123.00 Cr., marking an increase of 18.00 Cr..
However, the Borrowings (47.00 Cr.) are higher than the Reserves (30.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -23.00 | -18.00 | -23.00 | -35.00 | -32.00 | -29.00 | -63.00 | -32.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 227 | 32 | 39 | 14 | 29 | 11 | 24 | 19 |
| Inventory Days | 790 | 134 | 147 | 190 | 144 | 147 | 1,540 | 474 |
| Days Payable | 334 | 28 | 3 | 4 | 5 | 4 | 53 | 30 |
| Cash Conversion Cycle | 683 | 137 | 182 | 201 | 168 | 154 | 1,511 | 462 |
| Working Capital Days | 211 | 59 | 74 | 75 | 56 | 47 | 36 | 49 |
| ROCE % | 14% | 12% | 11% | 13% | 14% | 1% | 10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.39 | -0.45 | 0.62 | 3.57 | 2.39 |
| Diluted EPS (Rs.) | 0.39 | -0.45 | 0.62 | 3.57 | 2.39 |
| Cash EPS (Rs.) | 0.44 | -0.39 | 4.03 | 3.82 | 2.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 4.78 | 4.40 | 29.10 | 25.38 | 21.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 4.78 | 4.40 | 29.10 | 25.38 | 21.81 |
| Revenue From Operations / Share (Rs.) | 26.88 | 29.41 | 178.64 | 157.77 | 105.75 |
| PBDIT / Share (Rs.) | 1.08 | 0.12 | 7.89 | 6.94 | 5.11 |
| PBIT / Share (Rs.) | 1.02 | 0.06 | 7.61 | 6.68 | 4.92 |
| PBT / Share (Rs.) | 0.55 | -0.58 | 5.18 | 4.97 | 3.32 |
| Net Profit / Share (Rs.) | 0.38 | -0.45 | 3.74 | 3.56 | 2.39 |
| NP After MI And SOA / Share (Rs.) | 0.38 | -0.45 | 3.74 | 3.56 | 2.39 |
| PBDIT Margin (%) | 4.01 | 0.41 | 4.41 | 4.39 | 4.83 |
| PBIT Margin (%) | 3.81 | 0.22 | 4.26 | 4.23 | 4.64 |
| PBT Margin (%) | 2.07 | -1.99 | 2.89 | 3.14 | 3.13 |
| Net Profit Margin (%) | 1.43 | -1.54 | 2.09 | 2.25 | 2.26 |
| NP After MI And SOA Margin (%) | 1.43 | -1.54 | 2.09 | 2.25 | 2.26 |
| Return on Networth / Equity (%) | 8.07 | -10.34 | 12.86 | 14.04 | 10.97 |
| Return on Capital Employeed (%) | 20.39 | 1.44 | 24.85 | 23.49 | 19.23 |
| Return On Assets (%) | 3.35 | -3.35 | 4.45 | 4.53 | 3.93 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.03 | 0.11 | 0.16 |
| Total Debt / Equity (X) | 0.95 | 1.59 | 0.92 | 1.07 | 1.30 |
| Asset Turnover Ratio (%) | 2.15 | 2.13 | 2.20 | 1.08 | 1.09 |
| Current Ratio (X) | 1.56 | 1.35 | 1.49 | 1.50 | 1.63 |
| Quick Ratio (X) | 0.46 | 0.35 | 0.23 | 0.33 | 0.24 |
| Inventory Turnover Ratio (X) | 3.32 | 2.71 | 2.99 | 1.45 | 2.13 |
| Interest Coverage Ratio (X) | 2.31 | 0.18 | 3.25 | 4.05 | 3.20 |
| Interest Coverage Ratio (Post Tax) (X) | 1.83 | 0.30 | 2.54 | 3.08 | 2.50 |
| Enterprise Value (Cr.) | 148.16 | 327.05 | 531.16 | 126.80 | 89.37 |
| EV / Net Operating Revenue (X) | 0.60 | 1.22 | 1.95 | 0.52 | 0.55 |
| EV / EBITDA (X) | 15.01 | 293.97 | 44.13 | 11.99 | 11.46 |
| MarketCap / Net Operating Revenue (X) | 0.43 | 0.98 | 1.82 | 0.36 | 0.29 |
| Price / BV (X) | 2.43 | 6.62 | 11.16 | 2.25 | 1.41 |
| Price / Net Operating Revenue (X) | 0.43 | 0.98 | 1.82 | 0.36 | 0.29 |
| EarningsYield | 0.03 | -0.01 | 0.01 | 0.06 | 0.07 |
After reviewing the key financial ratios for Shreeoswal Seeds & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.39. This value is below the healthy minimum of 5. It has increased from -0.45 (Mar 24) to 0.39, marking an increase of 0.84.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.39. This value is below the healthy minimum of 5. It has increased from -0.45 (Mar 24) to 0.39, marking an increase of 0.84.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.44. This value is below the healthy minimum of 3. It has increased from -0.39 (Mar 24) to 0.44, marking an increase of 0.83.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.78. It has increased from 4.40 (Mar 24) to 4.78, marking an increase of 0.38.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.78. It has increased from 4.40 (Mar 24) to 4.78, marking an increase of 0.38.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 26.88. It has decreased from 29.41 (Mar 24) to 26.88, marking a decrease of 2.53.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 2. It has increased from 0.12 (Mar 24) to 1.08, marking an increase of 0.96.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.02. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 1.02, marking an increase of 0.96.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from -0.58 (Mar 24) to 0.55, marking an increase of 1.13.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 2. It has increased from -0.45 (Mar 24) to 0.38, marking an increase of 0.83.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 2. It has increased from -0.45 (Mar 24) to 0.38, marking an increase of 0.83.
- For PBDIT Margin (%), as of Mar 25, the value is 4.01. This value is below the healthy minimum of 10. It has increased from 0.41 (Mar 24) to 4.01, marking an increase of 3.60.
- For PBIT Margin (%), as of Mar 25, the value is 3.81. This value is below the healthy minimum of 10. It has increased from 0.22 (Mar 24) to 3.81, marking an increase of 3.59.
- For PBT Margin (%), as of Mar 25, the value is 2.07. This value is below the healthy minimum of 10. It has increased from -1.99 (Mar 24) to 2.07, marking an increase of 4.06.
- For Net Profit Margin (%), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from -1.54 (Mar 24) to 1.43, marking an increase of 2.97.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 8. It has increased from -1.54 (Mar 24) to 1.43, marking an increase of 2.97.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.07. This value is below the healthy minimum of 15. It has increased from -10.34 (Mar 24) to 8.07, marking an increase of 18.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 20.39. This value is within the healthy range. It has increased from 1.44 (Mar 24) to 20.39, marking an increase of 18.95.
- For Return On Assets (%), as of Mar 25, the value is 3.35. This value is below the healthy minimum of 5. It has increased from -3.35 (Mar 24) to 3.35, marking an increase of 6.70.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.95. This value is within the healthy range. It has decreased from 1.59 (Mar 24) to 0.95, marking a decrease of 0.64.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.15. It has increased from 2.13 (Mar 24) to 2.15, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has increased from 1.35 (Mar 24) to 1.56, marking an increase of 0.21.
- For Quick Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.35 (Mar 24) to 0.46, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.32. This value is below the healthy minimum of 4. It has increased from 2.71 (Mar 24) to 3.32, marking an increase of 0.61.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.31. This value is below the healthy minimum of 3. It has increased from 0.18 (Mar 24) to 2.31, marking an increase of 2.13.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.83. This value is below the healthy minimum of 3. It has increased from 0.30 (Mar 24) to 1.83, marking an increase of 1.53.
- For Enterprise Value (Cr.), as of Mar 25, the value is 148.16. It has decreased from 327.05 (Mar 24) to 148.16, marking a decrease of 178.89.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 1.22 (Mar 24) to 0.60, marking a decrease of 0.62.
- For EV / EBITDA (X), as of Mar 25, the value is 15.01. This value exceeds the healthy maximum of 15. It has decreased from 293.97 (Mar 24) to 15.01, marking a decrease of 278.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.43, marking a decrease of 0.55.
- For Price / BV (X), as of Mar 25, the value is 2.43. This value is within the healthy range. It has decreased from 6.62 (Mar 24) to 2.43, marking a decrease of 4.19.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.43, marking a decrease of 0.55.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.03, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Shreeoswal Seeds & Chemicals Ltd:
- Net Profit Margin: 1.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.39% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.07% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.83
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 12.5 (Industry average Stock P/E: 18.52)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.95
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Seeds/Tissue Culture/Bio Technology | Oswal House, Neemuch Madhya Pradesh 458441 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sanjay Kumar Baigani | Chairman & Managing Director |
| Mr. Anil Kumar Nahata | WholeTime Director & CEO |
| Mrs. Kiran Devi Begani | Non Exe.Non Ind.Director |
| Mr. Deepak Kothari | Ind. Non-Executive Director |
| Mr. Yash Wardhan Jain | Ind. Non-Executive Director |
| Mr. Sanjay Chordiya | Ind. Non-Executive Director |
| Mr. Umesh Kumar Sharma | Ind. Non-Executive Director |
| Mrs. Padma Nahta | Non Exe.Non Ind.Director |
| Mrs. Anjali Bamboria | Ind. Non-Executive Woman Director |
| Mr. Kanhaiya Lal Kumawat | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Shreeoswal Seeds & Chemicals Ltd?
Shreeoswal Seeds & Chemicals Ltd's intrinsic value (as of 21 January 2026) is ₹5.09 which is 62.85% lower the current market price of ₹13.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹125 Cr. market cap, FY2025-2026 high/low of ₹20.3/10.7, reserves of ₹30 Cr, and liabilities of ₹123 Cr.
What is the Market Cap of Shreeoswal Seeds & Chemicals Ltd?
The Market Cap of Shreeoswal Seeds & Chemicals Ltd is 125 Cr..
What is the current Stock Price of Shreeoswal Seeds & Chemicals Ltd as on 21 January 2026?
The current stock price of Shreeoswal Seeds & Chemicals Ltd as on 21 January 2026 is ₹13.7.
What is the High / Low of Shreeoswal Seeds & Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Shreeoswal Seeds & Chemicals Ltd stocks is ₹20.3/10.7.
What is the Stock P/E of Shreeoswal Seeds & Chemicals Ltd?
The Stock P/E of Shreeoswal Seeds & Chemicals Ltd is 12.5.
What is the Book Value of Shreeoswal Seeds & Chemicals Ltd?
The Book Value of Shreeoswal Seeds & Chemicals Ltd is 5.23.
What is the Dividend Yield of Shreeoswal Seeds & Chemicals Ltd?
The Dividend Yield of Shreeoswal Seeds & Chemicals Ltd is 0.00 %.
What is the ROCE of Shreeoswal Seeds & Chemicals Ltd?
The ROCE of Shreeoswal Seeds & Chemicals Ltd is 9.88 %.
What is the ROE of Shreeoswal Seeds & Chemicals Ltd?
The ROE of Shreeoswal Seeds & Chemicals Ltd is 8.41 %.
What is the Face Value of Shreeoswal Seeds & Chemicals Ltd?
The Face Value of Shreeoswal Seeds & Chemicals Ltd is 2.00.